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Abstract
Background: The aims of this study were to a) compare the lactate measurement of a Point of Care (POC)
handheld device to near patient blood gas analysers, and b) determine the differential reporting times
between the analysers.
Methods: A two-staged study; method comparison and prospective observational stages, was conducted. For
the first stage, blood samples were analysed on the i-STAT handheld device and the near patient blood gas
analysers (GEM 4000 and OMNI S). Results were compared using Pearson correlation coefficient and Bland-Altman tests.
For the second stage, we examined the differential reporting times of the POC device compared to the near patient
blood gas analysers in two Scottish hospitals. Differential reporting times were assessed using Mann–Whitney test and
descriptive statistics were reported with quartiles.
Results: Highly significant Pearson correlation coefficients (0.999 and 0.993 respectively) were found between i-STAT
and GEM 4000 and OMNI S. The Bland-Altman agreement method showed bias values of −0.03 and −0.24,
between i-STAT and GEM 4000 and OMNI S respectively. Median time from blood draw to i-STAT lactate
results was 5 min (Q1–Q3 5–7). Median time from blood draw to GEM 4000 lactate results was 10 min (Q1–Q3 7.75–13).
Median time from blood draw to OMNIS lactate results was 11 min (Q1–Q3 8–22). The i-STAT was significantly quicker
than both the GEM 4000 and the OMNIS (each p-value < 0.001). In addition, 18 of our study samples were sent to the
central laboratory for analysis due to a defect in the lactate module of OMNI S. The median time for these samples from
blood draw to availability of the central laboratory results at the clinical area was 133 min.
Conclusions: The POC handheld device produced accurate, efficient and timely lactate measurements with the potential
to influence clinical decision making sooner.
Introduction
Blood lactate is a useful biomarker to identify patients at
increased risk of mortality from sepsis. It is also an inde-
pendent predictor of mortality and critical care admis-
sion [1, 2]. Elevated blood lactate is associated with
mortality among critically ill patients [2, 3]. Early lactate
clearance is associated with a decreased mortality rate in
patients with severe sepsis [4]. Persistent elevation of
blood lactate of greater than 48 h in haemodynamically
stable postoperative patients has been shown to be
associated with an increased mortality rate [5]. Repeated
and timely monitoring is therefore important in the
management of patients with sepsis and in those with an
elevated lactate.
Lactate is measured using various analytical ap-
proaches including central laboratory methods, near
patient blood gas analysers and portable Point Of Care
(POC) handheld devices. The central laboratory ap-
proach involves transportation of blood samples to the
laboratory via porters or air-tube systems. This approach
is associated with delays such as; storing samples on ice
to avoid increases in lactate due to ex-vivo anaerobic
metabolism, transportation of samples to the laboratory
and centrifugation before analysis leading to possible
delays in the reporting of results to clinicians [6]. The
central laboratory approach is also associated with pro-
longed vein-to-brain time – the time it takes from blood
* Correspondence: Kevin.Rooney@uws.ac.uk
1Institute of Healthcare Policy and Practice, School of Health, Nursing and
Midwifery, University of the West of Scotland, Paisley, UK
5Intensive Care Unit, Royal Alexandra Hospital and Institute of Healthcare
Policy and Practice, University of the West of Scotland, Paisley, UK
Full list of author information is available at the end of the article
© 2016 Ismail et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ismail et al. Scandinavian Journal of Trauma, Resuscitation
and Emergency Medicine  (2015) 23:68 
DOI 10.1186/s13049-015-0151-x
draw to when the clinician becomes aware of the test re-
sults, resulting in a potential delay in clinical decision-
making. As POC technology has advanced, near patient
bench top blood gas analysers have been made available
for lactate testing. However these devices are not port-
able and their availability is usually restricted to individ-
ual specialist units, e.g. Emergency Departments (ED)
and Intensive Care Units (ICU). The advantage of blood
gas analysers is that they have a more rapid turnaround
time than central laboratory analysers [7]. However,
sample turnaround time may be affected by delays in
transportation to the ED or ICU, if the sample was
drawn outside these major units.
Lactate measurement is one of the elements of the
Sepsis Six and the Surviving Sepsis bundles [8]. The Sur-
vive Sepsis and Healthcare Improvement Scotland Sepsis
campaigns have both recommended delivery of the Sep-
sis Six bundle within one hour of identification of pa-
tients with sepsis [9, 10]. Lactate measurement devices
need to be placed at the point of need rather than in
centrally-accessed locations to assist healthcare practi-
tioners to achieve the one hour goal [7]. The potential
benefits of POC handheld devices in the clinical setting
are summarised in Table 1 [6, 8].
The aims of this study were: a) to compare lactate
measurements of the i-STAT handheld device to near
patient blood gas analysers situated in the ICU, and b)
to determine the differential reporting times between




The POC instruments compared in this study were: the
i-STAT (Abbott Point Of Care, Princeton, USA) com-
pared to the GEM Premier 4000 (Instrumentation
Laboratory, UK) and the OMNI S (Roche Diagnostics,
UK). Lactate assessment was performed by enzymatic
reaction on all three POC analysers.
The i-STAT is a portable handheld device that mea-
sures blood gas levels at the bedside. It employs a single-
use, disposable cartridge containing enzyme-coated
biosensors. The CG4+ cartridge was used for lactate
testing, according to the manufacturer’s instructions.
The i-STAT requires 95 μL of blood to measure lactate,
has a detection range from 0.30 to 20.00 mmol/L (ac-
cording to the manufacturer) and determines lactate
levels within 120 s. The i-STAT POC analysers are mon-
itored automatically by internal quality control systems
to monitor the integrity of the sample, sensors and fluid-
ics with each use of cartridge.
The GEM Premier 4000 and OMNI S are compact,
self-contained blood gas analysers that are located in the
ICU and ED of our study sites. They both employ a
multi-use cartridge containing enzyme-coated biosen-
sors. The GEM premier 4000 and OMNI S have detec-
tion ranges of 0.10 to 20.00 mmol/L and 0.20 to
20.00 mmol/L lactate respectively. Our study sites blood
gas analysers perform three types of automatic calibrations
at different intervals. While those calibrations are running,
testing cannot be performed leading to delays in analysing
urgent blood samples. In addition, some blood gas analy-
sers require a frequent replacement of the lactate elec-
trode. The i-STAT employs a similar quality control
system monitoring the quality of the cartridge, operators’
actions and the instrument performance.
Study settings
This study was conducted at two large university affiliated
district general suburban hospitals in Scotland (Royal
Alexandra Hospital, Paisley and University Hospital
Crosshouse). The Royal Alexandra Hospital [RAH] is a
650-bed hospital with a 7-bedded mixed medical and sur-
gical closed Intensive Care Unit (ICU). The ICU admits
approximately 350 adult patients a year (approx. 80 % of
admissions require Level 3 critical care) [11]. At this hos-
pital all lactate samples are measured using the blood gas
analyser GEM Premier 4000.
University Hospital Crosshouse [UHC] is a 645-bed
hospital with a 5-bedded mixed medical and surgical
closed ICU. The ICU admits approximately 270 adult
patients a year (approx. 70 % of admissions require Level
3 critical care) [11]. Within University Hospital Cross-
house, lactate samples are tested using the blood gas
analyser OMNI S.
The acute care setting in the second stage of the study
included both general medical and surgical wards as well
as three 12-bedded high dependency units (HDU). The
HDU within the RAH was an open mixed medical and
surgical HDU admitting approximately 1400 patients per
year. The two HDU’s within UHC were an open medical
and an open surgical HDU admitting approximately
1100 and 700 patients accordingly [11].
Study design
Patients
The study was approved by the ethical review board of
the University of the West of Scotland. The need for
Table 1 Advantages of POC testing in clinical settings
Advantages of POC testing
1) Simpler pre-analytical process 2) Requires small blood volume
e.g. 95 μl
3) Allows bedside testing& portability 4) Provides rapid results
5) Accelerates clinical decision-making
process
6) Allows healthcare practitioner
to deliver patient-centred care
7) Decreases time to treatment 8) Potential to improve patients
outcome
Ismail et al. Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine  (2015) 23:68 Page 2 of 7
patient consent was waived since the study was a service
evaluation and all data were analysed anonymously. All
of the patients were 16 years of age or older. Patients
less than the age of 16 years of age were excluded from
the study.
Methods
This study was conducted in two stages.
Method comparison stage
In the first stage, a method comparison for lactate was
performed using 97 heparinised arterial blood samples
from a total of 26 adult patients admitted to the ICUs of
our study sites. The patients had a variety of different
diagnoses requiring critical care. As this was a service
evaluation, sampling and simultaneous measurement
occurred at the discretion of the treating intensivist, who
was not involved in the study. Samples were collected
over a period of 2 weeks for each site. A single lot of
i-STAT cartridges were used for each site. A single ana-
lysis was performed on the i-STAT and immediately
thereafter (within median of 1–2 min for OMNI S and
GEM 4000 respectively) analysed on the blood gas ana-
lyser of each hospital (GEM Premier 4000/ OMNI S).
The analysers were run in accordance with their manu-
facturer’s recommendations. In this stage of the study,
the same researcher, who was an appropriately trained
laboratorian, performed all lactate testing at both sites.
Differential reporting times stage
In the second stage, a prospective observational study of
samples of adult patients from different wards was con-
ducted from January to July 2013. Advanced Nursing
Practitioners (ANPs) were involved in this stage as they
are the sepsis response team at the hospitals. The sepsis
response team were triggered when a patient had an ele-
vated early warning scoring system and clinical suspicion
of infection. The ANPs at both sites were trained on the
i-STAT before commencing the study. Lactate measure-
ment is a clinical guideline at both hospitals for all pa-
tients with suspected infection. Therefore, there was no
additional blood sample required for the purpose of this
study. A heparinised venous sample was collected from
patients suspected with infection. The sample was tested
on the i-STAT at the patients’ bedside and then the
standard procedure for lactate measurement was under-
taken. The time impact of the i-STAT testing on the
standard procedure for each hospital was taken into
consideration during data analysis.
The time of blood draw, i-STAT testing start time,
i-STAT results availability time, the starting and ending
time of blood gas analyser testing and the time of blood
gas analyser results availability at clinical area were
recorded on data collection sheets. Then the data were
entered into Microsoft Excel file (Microsoft Excel, 2010).
Statistical analysis
Pearson correlation coefficient was used to determine
the relationship between results from the POC handheld
device and the blood gas analysers. The Bland-Altman
method was used to determine the level of agreement
between the analysers based on values of bias and limits
of agreement [12].
The above tests provide the analytical difference
between the analysers. However, to assess the clinical
importance of the analytical difference between the ana-
lysers, patients were classified into three categories
based on their lactate levels; low (<2.5 mmol/L), medium
(2.5–3.99 mmol/L) and high (≥4 mmol/L). Lactate risk
level classification was based on previous medical litera-
ture which linked lactate levels to patients’ outcome [13].
For the second stage of the study, differential reporting
times were assessed using the Mann–Whitney test as
the data were skewed. Accordingly, descriptive statistics
were reported with quartiles for each site. All statistical
and graphical analyses were performed using the GraphPad
prism package (version 6.04, GraphPad Software Inc.). A
prior power calculation was not conducted as this was a
pilot study.
Results
Comparison of i-STAT against GEM premier 4000
The Clinical Laboratory Standards Institute (CLSI)
guidelines recommend a minimum of 40 observations in
method comparison studies [14]. Therefore, 50 represen-
tative samples were analysed on the i-STAT and the
GEM 4000 in parallel. Pearson correlation coefficient
analysis showed a strong correlation between the i-STAT
POC lactate and GEM 4000 analyser (r = 0.999). Bland-
Altman statistics showed an average bias for the i-STAT
of −0.03 lower than the GEM 4000 Premier with the
95 % limits of agreement ranging from −0.398 to 0.338
(Fig. 1).
Among the 50 samples (from 11 ICU patients) ana-
lysed on the GEM 4000 and the i-STAT; there were forty
one samples classified as low, seven samples as medium
and two samples as high lactate risk level categories. All
samples (50) from the two analysers fell in the same lac-
tate risk level categories (Table 2).
Comparison of i-STAT against OMNI S
Forty seven samples from 15 ICU patients were analysed
on the i-STAT and OMNI S in parallel. Pearson correl-
ation coefficient analysis showed a strong correlation be-
tween the i-STAT and OMNI S analyser (r = 0.993).
Bland-Altman statistics showed an average bias for
the i-STAT of - 0.24 lower than the OMNI S analyser
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with the 95 % limits of agreement ranging from -
0.407 to–0.079 (Fig. 2).
Among the 47 samples analysed on the OMNI S and
the i-STAT; there were 45 samples classified as low, two
samples as medium and zero samples as high lactate risk
level categories. All samples (47) from the two analysers
fell in the same lactate risk level categories (Table 2).
Differential reporting times
A total of 136 lactate measurements were collected in
this stage, but only 133 lactate results were available for
statistical analysis (50 samples from 47 patients at the
first hospital and 83 samples from 82 patients at the sec-
ond hospital). Median time from blood draw to availabil-
ity of the GEM 4000 blood gas analyser results at the
clinical area was 10 min ([Q1–Q3 7.75–13]). At our sec-
ond site, the median time from blood draw to availability
of the OMNI S results at the clinical area was 11 min
(Q1–Q3 8–22). Median time from blood draw to the
i-STAT results was 5 min at both sites (Q1–Q3 5–7).
The i-STAT was found to be significantly quicker at
both sites (each p-value < 0.001). The Bland-Altman
statistics in this stage showed an average bias for the
i-STAT of −0.12 and −0.53 lower than the GEM 4000
and OMNI S respectively.
Interestingly, toward the end of the study, the nurses
were informed that any lactate sample had to be sent to
the laboratory for analysis due to a UK wide defect in
the lactate module of the OMNI S. Consequently, the
last eighteen of our study samples were sent to the cen-
tral laboratory for analysis. This had led to an increase
in the median time from blood draw to availability of
the central laboratory results at the clinical area (median
133 min, Q1–Q 3 106–247). Those eighteen samples
were also included in the final analysis of the above
OMNI S data as this was a real life scenario which had
an impact on lactate results availability.
Discussion
Previous studies compared the i-STAT POC handheld
device to central laboratory analysers with a strong cor-
relation [13, 15]. However, our study is the first study to
compare the i-STAT to near patient blood gas analysers
for lactate. This study was conducted in two stages;
method comparison and prospective observational. In
the first stage of the study we compared the i-STAT
POC handheld device to GEM 4000 and OMNI S near
patient blood gas analysers located in the ICU of the
study sites. Overall, our findings have shown that the
i-STAT provides lactate results that are comparable
with the hospitals’ blood gas analysers, as evidenced
Fig. 1 Bland-Altman plot of the difference between the lactate (mmol/
L) measurements obtained by i-STAT and GEM 4000 analysers (calculated
by i-STAT lactate measurements – GEM 4000 lactate measurements)
versus the mean of the lactate measurements obtained by the two
analysers. Solid line represents bias; dashed lines represent upper and
lower 95 % limits of agreement
Table 2 Lactate risk category classification determined by the i-STAT and the blood gas analysers
Risk Category i-STAT GEM 4000 Risk Category i-STAT OMNI S
Low ≤2.5 mmol/L (n = 41) 41 41 Low ≤2.5 mmol/L (n = 45) 45 45
Intermediate 2.5–3.99 mmol/L (n = 7) 7 7 Intermediate 2.5–3.99 mmol/L (n = 2) 2 2
High ≥4 mmol/L (n = 2) 2 2 High ≥4 mmol/L (n = 0) 0 0
Legend: The above table shows that all lactate samples (50) analysed on the i-STAT and the GEM 4000 analysers fell in the same lactate risk level categories.
Similarly, all lactate samples (47) analysed on the i-STAT and the OMNI S fell in the same lactate risk level categories
Fig. 2 Bland -Altman plot of the differences between the lactate
(mmol/L) measurements obtained by i-STAT and OMNI S analysers
versus the mean of the lactate measurements obtained by the two
analysers. Solid line represents bias; dashed lines represent upper
and lower 95 % limits of agreement
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by the high Pearson correlation coefficient values and
a small bias. The i-STAT lactate measurements were
found to be lower than the GEM 4000 and OMNI S
results. This is consistent with a false elevation of the
lactate as the samples were collected without anti-
glycolytic preservatives and tested on the blood gas
analysers 1–2 min later after the i-STAT testing. The
Bland-Altman bias was found to be higher in the sec-
ond stage due to the prolonged time from blood draw
to the analysis of the samples on the blood gas analy-
sers (average of 7–8 min later of blood draw).
Our Bland-Altman figures have shown analytical varia-
tions in agreement across the range of the lactate mea-
surements. However, to assess whether those differences
are clinically acceptable we compared patients’ lactate
risk level classification using the i-STAT and the com-
parative methods. We found the methods are generally
comparable as lactate measurements from both analy-
sers classified patients within the same lactate risk level.
This shows that although there were small, clinically
acceptable, analytical differences, this would not have
affected clinical decisions.
In the second stage we determined the differential
reporting times from blood draw to availability of lactate
result at the clinical area. The findings from the second
stage demonstrated that the i-STAT was significantly
quicker than the near patient blood gas analysers in pro-
viding lactate results. Clinically, this can be translated
into earlier identification of patients with high lactate
levels and hence immediate clinical intervention. It also
means that lactate testing can be repeated rapidly to
determine lactate clearance and monitor patient re-
sponse to resuscitation therapy.
While a time differential of 5–6 min for the lactate
result may not initially appear to be clinically significant,
a systems thinking approach would reveal that the ana-
lysis of the sample at the patient’s bedside allows for less
opportunity for the sample to go missing as well as the
fact that it provides the clinician with the time to care
and to listen to their patient rather than take them away
from the bedside to transport the specimen. Lactate
measurement and result within an hour of recognition
or presentation of sepsis is also a recognised inter-
national quality indicator for providing best care. Conse-
quently, any marginal gain in providing a timely result
has the potential to not only improve care and outcome
but also avoid any financial disincentive for missing this
target.
The sensor defect in the OMNI S blood gas analyser dur-
ing the second stage reflects a real life situation within hos-
pitals. This had a large impact on delaying lactate reporting
times as the median time from blood draw to the lactate
results increased to 133 min. Consequently, this may have
had a negative impact on patients’ treatment and outcome.
Only a few studies have compared the differential
reporting times of lactate POC to central laboratory ana-
lysers [16, 17]. Those studies were conducted in a dif-
ferent clinical setting and observed different time
measurements to our study but their findings support
the need for implementing POC testing in hospitals.
Goyal et al. compared time from triage to POC lactate
and time from triage to availability of the central labora-
tory results. The authors found that the use of POC lac-
tate at triage decreased time to lactate result by a
median of 151 min [16]. Similarly, Gaieski et al. com-
pared differential reporting times between fingertip POC
lactate and central laboratory lactate. The researchers
found that the turnaround time of the fingertip POC lac-
tate was shorter than the central laboratory’s turnaround
time by a median of 65 min [17]. Those findings support
our central laboratory time findings and show that cen-
tral laboratory turnaround time may not be sufficient for
early lactate measurement. The impact of using a hand-
held POC device on early initiation of sepsis treatment
has not been widely researched. However, a recent study
by Singer et al. reported that the use of POC testing in
patients with sepsis reduced time to lactate results sig-
nificantly (p < 0.001), time to intravenous (IV) fluids
administration (p = 0.03) with a significant reduction in
mortality (p = 0.02) and ICU admission (p = 0.02) [18].
Singer et al. later demonstrated that the use of POC test-
ing in ED patients significantly reduced time to lactate
results and other biochemical tests (p < 0.001). It also re-
duced time to completion of Computed tomography
(CT) scanning in patients who received intravenous (IV)
contrast (p = 0.04) and reduced ED length of stay in
some patients [19]. Similarly, we believe that the use of
lactate POC testing can assist healthcare practitioners to
complete the Sepsis Six bundle within the target hour.
Thus, critically ill patients are identified sooner and
treated in a more timely manner.
The direct cost of POCT is found to be much higher
than the costs of central laboratory testing. However, the
use of portable POC handheld device has the potential
to reduce length of hospital stay, accelerate patient flow
in clinical settings and ultimately improve patient out-
comes [20, 21]. In the context of sepsis, 100,000
patients, with an average cost of £20,000 per patient, are
admitted to the UK hospitals annually due to sepsis [22].
The Parliamentary and Health Services reported recently
that £4,000 can be saved per sepsis case if the basic prin-
ciples of sepsis management are followed, namely the
Sepsis Six [22]. Therefore, the cost of using POC testing
in patients with sepsis could be outweighed by the long
term impact on patients’ outcome. Evidence of cost-
effectiveness analysis is required to explore the financial
impact of handheld POC lactate testing in patients with
sepsis.
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Institutions that are unable to meet the recommended
timeline for lactate measurement may benefit hugely
from using POC handheld devices in their clinical set-
tings. Pre-hospital or rural settings could also benefit
from using lactate POC handheld devices to identify
patients with increased lactate levels and increased pre-
dicted mortality. This would expedite the transfer of
those patients to the hospital.
Conclusion
In summary, we have shown that the i-STAT POC hand-
held device provides accurate, timely and efficient care
thereby supporting the institute of medicine domains of
quality healthcare. This was evidenced by our results that
showed the i-STATcorrelates strongly with the near patient
blood gas analysers. We have also shown that the POC
hand held device is significantly quicker than near patient
blood gas analysers and laboratory analysers. We believe
that the use of a POC handheld device facilitates immediate
clinical decision making and initiation of therapies for sep-
sis patients such as administration of antibiotics, fluid re-
suscitation and escalation of care. Further studies on the
impact of lactate POC testing on patients’ outcome are
required.
Key messages
 The i-STAT provides clinically acceptable lactate
results
 POC handheld device provides lactate results
significantly quicker than near patient blood gas
analysers and laboratory analysers
 The use of a lactate POC handheld device has the
potential to accelerate the decision-making process
in patients with sepsis
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